Compare Crispr Therapeutics AG (CRSP) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vipshop Holdings Ltd - ADR — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Vipshop Holdings Ltd - ADR trades at $15.06 (market cap $7.20B). The key difference: Vipshop Holdings Ltd - ADR is the larger of the two by market cap, and Vipshop Holdings Ltd - ADR pays a 4.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | VIPS | |
|---|---|---|
Market Cap | $5.23B | $7.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $20.68 |
52-Week Low | $44.34 | $12.92 |
Enterprise Value | $3.65B | $3.76B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Vipshop (VIPS) trades at $14.49, down 5.97% over 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The stock shows attractive valuation metrics, including a P/E of 6.79 and P/S of 0.48, alongside strong profitability with an 18.43% ROE. Recent earnings have been mixed, with Q1 2026 EPS meeting expectations, while the company pursues growth through an outlet strategy and REIT spin-off.
The outlook remains positive due to low valuations and profitability, but risks include revenue stagnation and competitive pressures. Analyst consensus is bullish with 53.57% buy ratings, supporting potential upside if earnings growth resumes in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
